Long-term effect of natalizumab in relapsing-remitting multiple sclerosis: TYSTEN cohort

被引：0
|
作者：
Bigaut, K. [1 ]
Fabacher, T. [2 ]
Kremer, L. [1 ]
Ongagna, J. -C. [1 ]
Kwiat-Kowski, A. [3 ]
Sellal, F. [4 ]
Ferriby, D. [5 ]
Courtois, S. [6 ]
Vermersch, P. [7 ]
Collongues, N. [1 ]
Zephir, H. [7 ]
De Seze, J. [1 ]
Outteryck, O. [7 ]
机构：
[1] Hop Univ Strasbourg, Dept Neurol, Strasbourg, France
[2] Hop Univ Strasbourg, Grp Methode Rech Clin, Strasbourg, France
[3] Grp Hop Inst Catholique Lille, Dept Neurol, Hop St Vincent, Lille, France
[4] Hop Civils Colmar, Dept Neurol, Colmar, France
[5] Ctr Hosp Tourcoing, Dept Neurol, Tourcoing, France
[6] Grp Hosp Reg Mulhouse & Sud Alsace, Dept Neurol, Mulhouse, France
[7] Ctr Hosp Reg Univ Lille, Dept Neurol, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1013
引用
收藏
页码：536 / 536
页数：1
相关论文
共 50 条
  • [1] Long-term effect of natalizumab in a French cohort of patients with relapsing-remitting multiple sclerosis: TYSTEN cohort
    Bigaut, Kevin
    Fabacher, Thibaut
    Collongues, Nicolas
    Kremer, Laurent
    Fleury, Marie-Celine
    Ongagna, Jean-Claude
    De Seze, Jerome
    NEUROLOGY, 2018, 90
  • [2] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [3] Natalizumab for relapsing-remitting multiple sclerosis
    Horga, A.
    Tintore, M.
    NEUROLOGIA, 2011, 26 (06): : 357 - 368
  • [4] Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
    Planas, Raquel
    Martin, Roland
    Sospedra, Mireia
    PATIENT-RELATED OUTCOME MEASURES, 2014, 5 : 25 - 33
  • [5] Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab
    Dekker, I
    Leurs, C. E.
    Hagens, M. H. J.
    van Kempen, Z. L. E.
    Kleerekooper, I
    Lissenberg-Witte, B., I
    Barkhof, F.
    Uitdehaag, B. M. J.
    Balk, L. J.
    Wattjes, M. P.
    Killestein, J.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 33 : 82 - 87
  • [6] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    JOURNAL OF NEUROLOGY, 2014, 261 : S303 - S303
  • [7] Natalizumab in spinal relapsing-remitting multiple sclerosis
    Zecca, C.
    Kamm, C.
    Riccitelli, G. C.
    Heldner, M.
    Caporro, M.
    Gobbi, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 457 - 457
  • [8] Long-term outcome of minocycline in relapsing-remitting multiple sclerosis
    Zhang, Y.
    Metz, L. M.
    Yong, V. W.
    Bell, R. B.
    Yeung, M.
    Patry, D.
    Mitchel, J. R.
    MULTIPLE SCLEROSIS, 2007, 13 (09): : 1226 - 1226
  • [9] Long-term adherence to interferon β therapy in relapsing-remitting multiple sclerosis
    Portaccio, E.
    Zipoli, V.
    Siracusa, G.
    Sorbi, S.
    Amato, M. P.
    EUROPEAN NEUROLOGY, 2008, 59 (3-4) : 131 - 135
  • [10] Relapsing-remitting multiple sclerosis: a long-term observation of immunomodulatory therapy
    Romanowski, F
    Straube, E
    Heinemann, J
    Rhein, R
    JOURNAL OF NEUROLOGY, 2004, 251 : 152 - 152
12345